ArticleScience advances2020
Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 84 citations in OpenAlex.
- Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions.Polymer science & technology (Washington, D.C.) · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Review
- The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy.Frontiers in immunology · 2026Review
- Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment.Frontiers in oncology · 2026Review
- Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics.Materials today. Bio · 2025Article
- Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy.Gels (Basel, Switzerland) · 2025Review
- Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells.Science advances · 2025Article
- Targeting TXN1 Induces G2M Phase Arrest and Apoptosis of Glioma Cells Through P38 MAPK Pathway.Applied biochemistry and biotechnology · 2025Article
- Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping.Nature communications · 2025Article
- CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.Journal of hematology & oncology · 2025Article
- Cytokines and oral cancer risk: Genetic evidence from a bidirectional Mendelian randomization study.Medicine · 2025Article
- Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Tumor cell-derived osteopontin promotes tumor fibrosis indirectly via tumor-associated macrophages.Journal of translational medicine · 2025Article
- Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses.Cell reports. Medicine · 2025Article
- Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.Frontiers in immunology · 2025Review
- The novel functions of chemokines in lung cancer progression.Frontiers in immunology · 2025Review
- Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment.Frontiers in immunology · 2025Review
- Prominent protumoral cellular compartments of the tumor microenvironment in triple-negative breast cancer.Frontiers in cell and developmental biology · 2025Review
- Acetyltransferase NAT10 promotes an immunosuppressive microenvironment by modulating CD8Molecular biomedicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 3 institutions in 1 country.
Hongmei ChenKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.ORCID 0000-0002-8555-0284
Xiuxiu CongKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Chenxi WuKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Xuan WuInstitute of Translational Medicine, China Medical University, Liaoning, China.
Jialiang WangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Kuirong MaoKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Jie LiInstitutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.ORCID 0000-0001-5992-3094
Ge ZhuKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Feiqi LiuKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Xiandi MengKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Jia SongKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Xu SunKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Xin WangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Shuhan LiuKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Shi ZhangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.
Xianzhu YangInstitutes for Life Sciences and School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Yanqiu SongKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.ORCID 0000-0002-8786-8835
Yong-Guang YangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.ORCID 0000-0002-8570-460X
Tianmeng SunKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China.ORCID 0000-0003-2261-4532
Jilin University · CNSouth China University of Technology · CNJinzhou Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCR9
Indexed as
AnimalsCD47 AntigenCD8-Positive T-LymphocytesChemokines, CCFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyMiceNanoparticlesNeoplasm MetastasisReceptors, CCRRNA, Small InterferingT-LymphocytesTriple Negative Breast NeoplasmsCC chemokine receptor 9CCL25 protein, humanCD47 AntigenChemokines, CCReceptors, CCRRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.